Public Outcomes Reporting Tied to Lower PCI Rates for Acute MI

Share this content:
Public Outcomes Reporting Tied to Lower PCI Rates for Acute MI
Public Outcomes Reporting Tied to Lower PCI Rates for Acute MI

THURSDAY, March 19, 2015 (HealthDay News) -- Public reporting of outcomes may be tied to lower rates of percutaneous revascularization and higher in-hospital mortality among acute myocardial infarction (AMI) patients in reporting states, compared to nonreporting states, according to a study published in the March 24 issue of the Journal of the American College of Cardiology.

Stephen W. Waldo, M.D., from Massachusetts General Hospital in Boston, and colleagues evaluated the association between public reporting with procedural management and outcomes among AMI patients using data from the Nationwide Inpatient Sample. Comparisons were made between patients in public reporting states (Massachusetts and New York; 57,629 patients) and those in regionally comparable states without public reporting (Connecticut, Maine, Maryland, New Hampshire, Rhode Island, and Vermont; 26,492 patients) from 2005 to 2011.

The researchers found that percutaneous revascularization was performed less often in public reporting states than in nonreporting states (odds ratio [OR], 0.81), especially among older patients (OR, 0.75), those with Medicare insurance (OR, 0.75), and those presenting with ST-segment elevation MI (OR, 0.63). Overall, there were higher adjusted in-hospital mortality rates among patients with AMI in public reporting states (OR, 1.21), compared to those in nonreporting states, although this was predominately seen in patients who did not receive percutaneous revascularization in public reporting states (adjusted OR, 1.30).

"It is troubling to face the possibility that public reporting of outcome data for percutaneous coronary intervention might, in fact, be associated with the unintended consequence of lower percutaneous coronary intervention rates in this patient population and in what could be potentially considered a deviation from the standard of care, resulting in worse outcomes," writes the author of an accompanying editorial.

One author disclosed financial ties to the medical device industry.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »